Numerous disease-related variables could serve as prognostic and predictive factors for treatment outcomes with sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer.
- A Network of Your PeersView more >>
Most Popular Right Now
Gary M. Kirsh, MD, Earl L. Walz, and Pamela Skurkay discuss the integration of the autologous cellular immunotherapy sipuleucel-T (Provenge) into clinical practice for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. View Now